Metabolic and Structural Consequences of GM3 Synthase Deficiency: Insights from an HEK293-T Knockout Model
<b>Background</b>: GM3 Synthase Deficiency (GM3SD) is a rare autosomal recessive neurodevelopmental disease characterized by recurrent seizures and neurological deficits. The disorder stems from mutations in the <i>ST3GAL5</i> gene, encoding GM3 synthase (GM3S), a key enzyme...
Saved in:
| Main Authors: | Elena Chiricozzi, Giulia Lunghi, Manuela Valsecchi, Emma Veronica Carsana, Rosaria Bassi, Erika Di Biase, Dorina Dobi, Maria Grazia Ciampa, Laura Mauri, Massimo Aureli, Kei-ichiro Inamori, Jin-ichi Inokuchi, Sandro Sonnino, Maria Fazzari |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-04-01
|
| Series: | Biomedicines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2227-9059/13/4/843 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
C18:0 GM3 ganglioside’s efficacy in LPS-induced parkinsonism: neuroprotection, inflammatory inhibition and gliosis mitigation
by: Tsung-Ta Liu, et al.
Published: (2025-07-01) -
The presence of Mycoplasma pneumoniae infection and GM1 ganglioside antibodies in Guillain-Barré syndrome
by: Mridula B Sharma, et al.
Published: (2011-03-01) -
Disease‐modifying effects of ganglioside GM1 in Huntington's disease models
by: Melanie Alpaugh, et al.
Published: (2017-10-01) -
Elevation of ganglioside degradation pathway drives GM2 and GM3 within amyloid plaques in a transgenic mouse model of Alzheimer's disease
by: Wenxuan Wang, et al.
Published: (2025-02-01) -
Evaluation of the Landscape of Pharmacodynamic Biomarkers in GM1 and GM2 Gangliosidosis
by: Sydney Stern, et al.
Published: (2025-03-01)